Citadel Advisors’s Actinium Pharmaceuticals ATNM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $101K | Sell |
101,100
-13,600
| -12% | -$16.2K | ﹤0.01% | 12018 |
|
|
2025
Q4 | $156K | Buy |
114,700
+89,600
| +357% | +$131K | ﹤0.01% | 11272 |
|
|
2025
Q3 | $40.2K | Sell |
25,100
-14,100
| -36% | -$23K | ﹤0.01% | 12295 |
|
|
2025
Q2 | $54.9K | Sell |
39,200
-2,000
| -5% | -$2.99K | ﹤0.01% | 11725 |
|
|
2025
Q1 | $66.3K | Sell |
41,200
-4,000
| -9% | -$5.08K | ﹤0.01% | 11988 |
|
|
2024
Q4 | $57K | Sell |
45,200
-20,000
| -31% | -$31K | ﹤0.01% | 12245 |
|
|
2024
Q3 | $123K | Buy |
65,200
+39,700
| +156% | +$157K | ﹤0.01% | 10844 |
|
|
2024
Q2 | $189K | Buy |
25,500
+1,600
| +7% | +$13.2K | ﹤0.01% | 10025 |
|
|
2024
Q1 | $187K | Buy |
23,900
+5,900
| +33% | +$37.9K | ﹤0.01% | 10424 |
|
|
2023
Q4 | $91.4K | Sell |
18,000
-9,400
| -34% | -$48.4K | ﹤0.01% | 11046 |
|
|
2023
Q3 | $162K | Sell |
27,400
-12,900
| -32% | -$85.8K | ﹤0.01% | 10232 |
|
|
2023
Q2 | $299K | Buy |
40,300
+3,300
| +9% | +$28.1K | ﹤0.01% | 9059 |
|
|
2023
Q1 | $350K | Sell |
37,000
-57,400
| -61% | -$606K | ﹤0.01% | 9054 |
|
|
2022
Q4 | $1.01M | Sell |
94,400
-46,800
| -33% | -$475K | ﹤0.01% | 6808 |
|
|
2022
Q3 | $1.04M | Sell |
141,200
-78,500
| -36% | -$488K | ﹤0.01% | 6894 |
|
|
2022
Q2 | $1.06M | Sell |
219,700
-318,200
| -59% | -$1.81M | ﹤0.01% | 6897 |
|
|
2022
Q1 | $2.75M | Buy |
537,900
+433,700
| +416% | +$2.28M | ﹤0.01% | 5387 |
|
|
2021
Q4 | $626K | Sell |
104,200
-32,100
| -24% | -$241K | ﹤0.01% | 9113 |
|
|
2021
Q3 | $1.21M | Buy |
136,300
+30,800
| +29% | +$214K | ﹤0.01% | 7656 |
|
|
2021
Q2 | $835K | Buy |
105,500
+19,900
| +23% | +$156K | ﹤0.01% | 8827 |
|
|
2021
Q1 | $652K | Sell |
85,600
-52,600
| -38% | -$447K | ﹤0.01% | 9106 |
|
|
2020
Q4 | $1.08M | Buy |
+138,200
| New | +$1.5M | ﹤0.01% | 6655 |
|
|
2019
Q1 | – | Sell |
-337
| Closed | -$4K | – | 9230 |
|
|
2018
Q4 | $4K | Hold |
337
| – | – | ﹤0.01% | 8989 |
|
|
2018
Q3 | $7K | Sell |
337
-733
| -69% | -$14.9K | ﹤0.01% | 9120 |
|
|
2018
Q2 | $21K | Buy |
+1,070
| New | +$13.6K | ﹤0.01% | 8638 |
|
|
2017
Q4 | – | Sell |
-970
| Closed | -$17K | – | 7936 |
|
|
2017
Q3 | $17K | Buy |
970
+457
| +89% | +$10K | ﹤0.01% | 7383 |
|
|
2017
Q2 | $19K | Buy |
+513
| New | +$21.5K | ﹤0.01% | 7301 |
|
|
2016
Q4 | – | Sell |
-650
| Closed | -$26K | – | 7226 |
|
|
2016
Q3 | $26K | Buy |
+650
| New | +$33.4K | ﹤0.01% | 6981 |
|
|
2016
Q2 | – | Sell |
-333
| Closed | -$20K | – | 6801 |
|
|
2016
Q1 | $20K | Buy |
333
+10
| +3% | +$631 | ﹤0.01% | 6454 |
|
|
2015
Q4 | $31K | Buy |
323
+130
| +67% | +$8.64K | ﹤0.01% | 7638 |
|
|
2015
Q3 | $10K | Buy |
+193
| New | +$12.9K | ﹤0.01% | 8464 |
|
Other funds holding ATNM
VCM
GS
VFT
Citadel Advisors's ATNM Position: Q4 2025 in Review
Citadel Advisors sold out of Actinium Pharmaceuticals (ATNM) in Q4 2025, closing a stake of 126,615 shares — an estimated $185K sold.
Citadel Advisors first reported a position in ATNM in Q2 2015 and held it in 27 quarters. The position peaked at $1.29M in Q4 2022. 60 funds tracked by Wall St. Rank hold ATNM as of Q4 2025.
- Citadel Advisors reported no remaining Actinium Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
- Citadel Advisors sold 126,615 Actinium Pharmaceuticals shares in Q4 2025, an estimated $185K.
- Citadel Advisors first reported a position in Actinium Pharmaceuticals in Q2 2015 and held it in 27 quarters.
- Citadel Advisors's Actinium Pharmaceuticals position peaked at $1.29M in Q4 2022.
- 60 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q4 2025.
Based on Citadel Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.